When a protocol moves from one laboratory to another, the receiving team inherits more than a method sheet. It inherits a chain of assumptions about materials, documentation and traceability. A batch Certificate of Analysis (CoA) should be read before an order is placed, not after the box arrives, because the CoA is where the catalogue record, the actual vial and the receiving laboratory’s acceptance criteria meet. All materials discussed here are for controlled in-vitro laboratory research only; they are not for human or veterinary use.
Why the Batch CoA Is Part of the Protocol Transfer, Not a Post-Order Attachment
The first mistake is to treat the CoA as a quality certificate that can be filed once the shipment is booked. In a lab-to-lab transfer, the CoA is a handover document. It allows the receiving laboratory to check that the material being ordered matches the material described in the transferred protocol, and that the documentation package is complete enough for local review. A catalogue page can show a product name, pack size and a headline purity figure, but it cannot replace the batch-specific record. The researcher or materials manager should therefore read the CoA before raising a purchase request, especially when the receiving lab has never handled that supplier’s material before.
A useful CoA is traceable to the vial in hand and to the order being considered. Research Sciences describes a vial label reference format that combines the SKU code and expiry date, such as BPC10-03/27, linking to the corresponding CoA. That reference is more useful than a generic product name when discussing documentation with a supplier. The same supplier’s FAQs explain that restocked products may carry the same Internal Test Reference (ITR) as earlier stock, and that an ITR links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Vial cap colour may also vary and is not an indicator of identity, analytical quality or manufacturing origin. These points matter during a transfer because the receiving lab may compare an old CoA from the sending lab with a new batch being ordered, and the two documents may not represent the same production lot.
This is also why the CoA should be read against the protocol’s acceptance criteria, not merely against the supplier’s homepage. Research Sciences states that every product includes a CoA for purity and identity by HPLC, and that compounds are independently tested with final UK verification before release. The site also describes an expanded testing framework covering heavy metals and endotoxin screening alongside CoA documentation. Those are the supplier’s published positions and are a sensible starting point, but the researcher should open the actual batch document and confirm which results are present. Published lines such as “≥99% Verified Purity” and “UK Research Materials Over 99.1% Purity” are marketing statements that can change; the exact purity should be checked on the batch CoA and reconfirmed against the live site before the order is approved. Materials remain research-use-only and are not for human or veterinary use.
What to Read on the CoA Before the Purchase Request Is Raised
Read the CoA in a fixed order so that the same checks are repeated for every transfer. First confirm the product name, batch or lot reference, ITR where present, testing date and method. Then check that the vial label reference on the catalogue item can be matched to the CoA supplied for that batch. A materials manager should record the reference in the internal order file and quote it when contacting the supplier about documentation. Do not rely on cap colour, packaging appearance or a restock notice as evidence of continuity. If the document is for a different ITR or a different batch reference, treat it as a separate record until the supplier confirms the link in writing.
When you open the supplier’s Uk peptides catalogue to confirm the item record, treat the headline purity claim as a prompt for verification rather than a substitute for the batch CoA. Check whether the CoA states identity and purity by HPLC and whether any contaminant screening results are included or held in an associated report. The homepage lists “CoAs Janoshik Analytical Reports”; if that wording forms part of the supplier’s current published material, the researcher should still open and check the CoA that accompanies the specific batch. Do not invent pass/fail limits or assume that a method named on one certificate applies to every product. Where the CoA is silent on a test that the receiving laboratory requires, raise the question before ordering rather than after dispatch.
Reading the Method, Not Just the Number
A purity percentage without context can mislead a transfer review. The CoA should be read alongside the product identity, the analytical method named, the batch reference and the storage guidance. If the receiving laboratory’s protocol was written around a particular grade or documentation set, the CoA must be assessed against that requirement. This is a documentation exercise, not a therapeutic or clinical assessment. The supplier’s catalogue is for controlled laboratory and analytical research, and the purchaser remains responsible for lawful use, safe handling, storage and disposal, including compliance with COSHH and laboratory safety standards.
Turning a CoA Review into an Order and Handover Decision
Once the CoA has been read, the order decision should be recorded in the transfer file. A simple check is to ask whether the receiving laboratory can answer three questions from the documents alone: which batch is being ordered, what analytical record supports it, and how it will be stored and handled on arrival. For lyophilised materials, Research Sciences guidance says to store at −20°C or below, sealed with desiccant and protected from moisture, heat and light; vials should be allowed to reach room temperature before opening in a clean laboratory environment, and repeated freeze–thaw cycles should be avoided. Reconstituted material is less stable and should be stored at 2–8°C for short-term laboratory use. Reconstitution language belongs strictly inside an in-vitro workflow—diluent volume and concentration for an assay—not administration. The supplier’s free reconstitution calculator is for laboratory research use only and must not be used for human or veterinary dosing.
If the protocol calls for more than one peptide, check that the order is structured for individual vials and controlled experimental design. Research Sciences states that it does not supply blended peptides and recommends buying peptides individually and combining only within a controlled experimental design. For dispatch planning, the published terms say all orders are dispatched the next working day, shipped via Royal Mail Tracked 24, which usually delivers the following working day as a Royal Mail estimate; delivery times are estimates and should be reconfirmed at checkout. These fulfilment details do not replace the CoA review, but they belong in the same order file because the receiving lab may need to schedule receipt, storage and documentation checks together.
Before the purchase request is approved, attach the batch CoA to the protocol transfer record and note the vial reference, batch or ITR reference, storage route and any open documentation query. The receiving laboratory should then compare the document with its own in-vitro acceptance criteria and confirm that the material is suitable for the intended research application. If the CoA cannot be reconciled with the item being ordered, pause the order and resolve the documentary gap first. This approach keeps the transfer auditable, keeps the material traceable and reinforces the research-use-only status of the products: they are not medicines, medical devices, injectables, treatments or food supplements, and they are not for human or veterinary use.
SantosJGardner